Undisclosed	O
HIV	B:C0019693
infection	I:C0019693
and	O
art	O
use	O
in	O
the	O
kenya	O
AIDS	I:C0038951
indicator	I:C0038951
survey	I:C0038951
2012	I:C0038951
:	O
relevance	O
to	O
targets	O
for	O
HIV	O
diagnosis	O
and	O
treatment	O
in	O
kenya	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
and	O
art	B:C1963724
use	O
in	O
the	O
kenya	O
AIDS	I:C0038951
indicator	I:C0038951
survey	I:C0038951
2012	I:C0038951
:	O
relevance	O
to	O
targets	O
for	O
HIV	O
diagnosis	O
and	O
treatment	O
in	O
kenya	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
and	O
art	O
use	O
in	O
the	O
kenya	B:C0038951
AIDS	I:C0038951
indicator	I:C0038951
survey	I:C0038951
2012	I:C0038951
:	O
relevance	O
to	O
targets	O
for	O
HIV	O
diagnosis	O
and	O
treatment	O
in	O
kenya	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
and	O
art	O
use	O
in	O
the	O
kenya	O
AIDS	I:C0038951
indicator	I:C0038951
survey	I:C0038951
2012	I:C0038951
:	O
relevance	O
to	O
targets	O
for	O
HIV	O
diagnosis	O
and	O
treatment	B:C0087111
in	O
kenya	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
and	O
art	O
use	O
in	O
the	O
kenya	O
AIDS	I:C0038951
indicator	I:C0038951
survey	I:C0038951
2012	I:C0038951
:	O
relevance	O
to	O
targets	O
for	O
HIV	O
diagnosis	O
and	O
treatment	O
in	O
kenya	B:C0022558
.	O

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	B:C0019693
infection	I:C0019693
and	O
antiretroviral	O
(	I:C1963724
ARV	I:C1963724
)	I:C1963724
therapy	I:C1963724
(	O
ART	O
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
coverage	O
in	O
Kenya	O
.	O

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
antiretroviral	B:C1963724
(	I:C1963724
ARV	I:C1963724
)	I:C1963724
therapy	I:C1963724
(	O
ART	O
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
coverage	O
in	O
Kenya	O
.	O

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
antiretroviral	O
(	I:C1963724
ARV	I:C1963724
)	I:C1963724
therapy	I:C1963724
(	O
ART	B:C1963724
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
coverage	O
in	O
Kenya	O
.	O

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
antiretroviral	O
(	I:C1963724
ARV	I:C1963724
)	I:C1963724
therapy	I:C1963724
(	O
ART	O
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	B:C1963724
coverage	O
in	O
Kenya	O
.	O

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
antiretroviral	O
(	I:C1963724
ARV	I:C1963724
)	I:C1963724
therapy	I:C1963724
(	O
ART	O
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
coverage	O
in	O
Kenya	B:C0022558
.	O

HIV	O
-	O
positive	O
dried	B:C0178913
blood	I:C0178913
spot	I:C0178913
samples	I:C0178913
from	O
Kenya	O
's	I:C0038951
second	I:C0038951
AIDS	I:C0038951
Indicator	I:C0038951
Survey	I:C0038951
were	O
tested	O
for	O
an	O
ARV	O
biomarker	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
.	O

HIV	O
-	O
positive	O
dried	O
blood	I:C0178913
spot	I:C0178913
samples	I:C0178913
from	O
Kenya	B:C0038951
's	I:C0038951
second	I:C0038951
AIDS	I:C0038951
Indicator	I:C0038951
Survey	I:C0038951
were	O
tested	O
for	O
an	O
ARV	O
biomarker	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
.	O

HIV	O
-	O
positive	O
dried	O
blood	I:C0178913
spot	I:C0178913
samples	I:C0178913
from	O
Kenya	O
's	I:C0038951
second	I:C0038951
AIDS	I:C0038951
Indicator	I:C0038951
Survey	I:C0038951
were	O
tested	O
for	O
an	O
ARV	O
biomarker	B:C0005516
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
.	O

HIV	O
-	O
positive	O
dried	O
blood	I:C0178913
spot	I:C0178913
samples	I:C0178913
from	O
Kenya	O
's	I:C0038951
second	I:C0038951
AIDS	I:C0038951
Indicator	I:C0038951
Survey	I:C0038951
were	O
tested	O
for	O
an	O
ARV	O
biomarker	O
by	O
liquid	B:C4049918
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
.	O

Estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	B:C1963724
use	O
based	O
on	O
self	O
-	I:C2700446
report	I:C2700446
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
based	O
on	O
ARV	O
testing	O
.	O

Estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
use	O
based	O
on	O
self	B:C2700446
-	I:C2700446
report	I:C2700446
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
based	O
on	O
ARV	O
testing	O
.	O

Estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
use	O
based	O
on	O
self	O
-	I:C2700446
report	I:C2700446
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	B:C0019693
infection	I:C0019693
and	O
ART	O
use	O
based	O
on	O
ARV	O
testing	O
.	O

Estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
use	O
based	O
on	O
self	O
-	I:C2700446
report	I:C2700446
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	B:C1963724
use	O
based	O
on	O
ARV	O
testing	O
.	O

Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	B:C0019693
infection	I:C0019693
and	O
ART	O
use	O
among	O
persons	O
on	O
ART	O
.	O

Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	B:C1963724
use	O
among	O
persons	O
on	O
ART	O
.	O

Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
among	O
persons	B:C0027361
on	O
ART	O
.	O

Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
among	O
persons	O
on	O
ART	B:C1963724
.	O

Among	O
559	O
HIV	O
-	O
positive	O
samples	B:C0178913
,	O
the	O
ARV	O
biomarker	O
was	O
detected	O
in	O
42.5	O
%	O
(	O
CI	O
37.4-47.7	O
)	O
.	O

Among	O
559	O
HIV	O
-	O
positive	O
samples	O
,	O
the	O
ARV	O
biomarker	B:C0005516
was	O
detected	O
in	O
42.5	O
%	O
(	O
CI	O
37.4-47.7	O
)	O
.	O

Among	O
559	O
HIV	O
-	O
positive	O
samples	O
,	O
the	O
ARV	O
biomarker	O
was	O
detected	B:C0442726
in	O
42.5	O
%	O
(	O
CI	O
37.4-47.7	O
)	O
.	O

ARV	B:C0599685
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	O
HIV	O
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	O
no	O
previous	O
HIV	O
test	I:C1321876
.	O

ARV	O
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	B:C1963724
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	O
HIV	O
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	O
no	O
previous	O
HIV	O
test	I:C1321876
.	O

ARV	O
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	B:C1963724
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	O
HIV	O
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	O
no	O
previous	O
HIV	O
test	I:C1321876
.	O

ARV	O
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	B:C0700287
HIV	O
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	O
no	O
previous	O
HIV	O
test	I:C1321876
.	O

ARV	O
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	O
HIV	B:C0854048
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	O
no	O
previous	O
HIV	O
test	I:C1321876
.	O

ARV	O
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	O
HIV	O
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	B:C0700287
no	O
previous	O
HIV	O
test	I:C1321876
.	O

ARV	O
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	O
HIV	O
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	O
no	B:C1513916
previous	O
HIV	O
test	I:C1321876
.	O

ARV	O
drugs	I:C0599685
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-28.6	O
)	O
reporting	O
HIV	O
-	I:C0854048
negative	I:C0854048
status	I:C0854048
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	O
no	O
previous	O
HIV	B:C1321876
test	I:C1321876
.	O

After	O
correcting	O
for	O
undisclosed	O
HIV	B:C0019693
infection	I:C0019693
and	O
ART	O
use	O
,	O
diagnosed	O
HIV	O
increased	O
from	O
46.9	O
%	O
to	O
57.2	O
%	O
and	O
ART	O
coverage	O
increased	O
from	O
31.8	O
%	O
to	O
42.8	O
%	O
.	O

After	O
correcting	O
for	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	B:C1963724
use	O
,	O
diagnosed	O
HIV	O
increased	O
from	O
46.9	O
%	O
to	O
57.2	O
%	O
and	O
ART	O
coverage	O
increased	O
from	O
31.8	O
%	O
to	O
42.8	O
%	O
.	O

After	O
correcting	O
for	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
,	O
diagnosed	O
HIV	O
increased	O
from	O
46.9	O
%	O
to	O
57.2	O
%	O
and	O
ART	B:C1963724
coverage	O
increased	O
from	O
31.8	O
%	O
to	O
42.8	O
%	O
.	O

Undisclosed	O
HIV	B:C0019693
infection	I:C0019693
on	O
ART	O
was	O
associated	O
with	O
being	O
aged	O
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	O
provider	I:C0018724
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	O
use	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
on	O
ART	B:C1963724
was	O
associated	O
with	O
being	O
aged	O
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	O
provider	I:C0018724
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	O
use	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
on	O
ART	O
was	O
associated	O
with	O
being	O
aged	B:C0001792
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	O
provider	I:C0018724
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	O
use	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
on	O
ART	O
was	O
associated	O
with	O
being	O
aged	O
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	B:C0018724
provider	I:C0018724
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	O
use	O
.	O

Undisclosed	O
HIV	O
infection	I:C0019693
on	O
ART	O
was	O
associated	O
with	O
being	O
aged	O
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	O
provider	I:C0018724
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	B:C1963724
use	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	B:C0019693
infection	I:C0019693
and	O
ART	O
use	O
while	O
on	O
ART	O
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	O
coverage	O
by	O
131,000	O
persons	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	B:C1963724
use	O
while	O
on	O
ART	O
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	O
coverage	O
by	O
131,000	O
persons	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
while	O
on	O
ART	B:C1963724
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	O
coverage	O
by	O
131,000	O
persons	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
while	O
on	O
ART	O
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	B:C0027361
and	O
ART	O
coverage	O
by	O
131,000	O
persons	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
while	O
on	O
ART	O
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	B:C1963724
coverage	O
by	O
131,000	O
persons	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	O
infection	I:C0019693
and	O
ART	O
use	O
while	O
on	O
ART	O
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	O
coverage	O
by	O
131,000	O
persons	B:C0027361
.	O

Supplementing	O
self	B:C2700446
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	B:C1963724
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	B:C1963724
use	O
in	O
national	O
population	O
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	B:C1257890
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-	O
based	O
sero	B:C0019700
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	B:C0184511
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	B:C1283169
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	O
of	O
treatment	B:C0087111
targets	O
in	O
countries	O
.	O

Supplementing	O
self	O
-	I:C2700446
reported	I:C2700446
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-	O
based	O
sero	O
-	I:C0019700
surveys	I:C0019700
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	B:C0454664
.	O

